In a phase 3 trial, patients with advanced BRAF (V600E)-mutant metastatic colorectal cancer (mCRC) after one or two lines of therapy who received a triple-combination of encorafenib (Braftovi, Array Biopharma), binimetinib (Mektovia, Array Biopharma), and cetuximab (Erbitux, Eli Lilly) almost doubled their overall survival rate.
Patients in the BEACON CRC trial who received the “Braftovi Triplet” therapy showed a statistically significant improvement in overall survival and objective response rate compared to patients receiving regimens with cetuximab plus irinotecan. Median progression-free survival for patients receiving Braftovi Triplet was 4.3 months compared with 1.5 months.
The triple combination therapy could be a potential new standard-of-care regimen for a patient population who currently have few treatment options available to them.
Colorectal cancer is the second most common cancer in women and the third most common type in men. In 2018, approximately 140,250 people were diagnosed with colon or rectal cancer in the U.S., and worldwide, there were about 18 million new diagnoses. Each year, close to 50,000 people die from the disease.
The specific BRAF mutations occur in about 15% of patients with mCRC, and typically indicate a poor prognosis. The V600 mutation is the most common BRAF mutation, and increases the risk of mortality more than twofold compared with the normal or wildtype BRAF.
The response rates in second-line patients were 34% with the triple combination compared with 22% for the double combination and 2% for standard-of-care chemotherapy.
Source: BioSpace, July 8, 2019